• Kosuke Katayama, Naoya Matsuda, Kiyohide Kakuta, Masato Naraoka, Atsuhito Takemura, Seiko Hasegawa, Kenichi Akasaka, Norihito Shimamura, Katsuhiro Itoh, Kenichiro Asano, Hiromu Konno, and Hiroki Ohkuma.
• 1 Department of Neurosurgery, Hirosaki University Graduate School of Medicine , Aomori, Japan .
• J. Neurotrauma. 2018 Jul 1; 35 (13): 1537-1542.

AbstractThe relatively high rate of post-operative recurrence in the treatment of chronic subdural hematoma (CSDH) is a significant problem. Goreisan is an herbal medicine that exhibits a hydragogue effect by inhibiting the expression of aquaporins, and its efficacy in preventing post-operative CSDH recurrence has been suggested by several case trials. This multi-center prospective randomized controlled trial was performed to investigate the preventative effect of goreisan on post-operative CSDH recurrence. Patients with symptomatic CSDH over 60 years old undergoing burr hole surgery were enrolled in this study. The patients were randomly allocated to the control group or the goreisan group, in which oral administration of goreisan (7.5 g daily) was continued for 12 weeks. The primary end-point was the post-operative recurrence rate at 12 weeks and the secondary end-point was hematoma volume reduction rates on computed tomography scan at 12 weeks. The analyses were performed not only on patients of all ages older than 60 years, but also on patients divided into those over or under 75 years old. One hundred and eighty patients were followed and analyzed (the control group, n = 88; the goreisan group, n = 92). The recurrence rates considering patients of all ages and patients under 75 years old were relatively low in the goreisan group but without a significant difference. The hematoma volume reduction rates showed no significant difference. Based on the results of the present study, a larger-scale study including more cases is necessary in future to confirm the efficacy of goreisan.

21 keywords...

hide…